EU MDR Readiness Review
Panabistics performs a reviewer-style stress test of EU MDR technical documentation, GSPR evidence, clinical evaluation, PMS/PMCF, risk management, labeling, UDI, and verification and validation evidence before Notified Body review, remediation, transfer, or CE marking strategy decisions.
Part of Panabistics Regulatory Readiness Stress Tests. Navigating the Future of MedTech Compliance.
An MDR technical file can contain many documents and still fail under reviewer scrutiny if the evidence is not consistent, traceable, or defensible. Panabistics reviews the file as a connected evidence system, including intended purpose, claims, classification, GSPR mapping, risk controls, clinical rationale, PMS/PMCF strategy, labeling, and verification and validation evidence.
This is a consultant-reviewed technical documentation readiness review designed to identify likely weaknesses before formal Notified Body review or remediation.
Review Scope
Deliverables
Reviewer-style findings focused on likely technical documentation challenges.
Practical tracker for documentation gaps, severity, regulatory basis, and remediation ownership.
Assessment of whether GSPR mapping, evidence, and supporting records align across the technical file.
Review of whether clinical evaluation, PMS, and PMCF strategy and evidence are consistent and defensible.
Assessment of IFU, labeling, UDI, and claims against supporting evidence and intended purpose.
Practical next steps to strengthen the technical file before Notified Body review or transfer.
Support to revise documents and close gaps, scoped separately as needed.
Audience
This service does not replace Notified Body review, CE certification, legal advice, testing, clinical evaluation ownership, or the manufacturer’s responsibility for MDR compliance. It is an independent readiness review designed to identify likely technical documentation weaknesses before formal review or remediation.
Request a Review
Tell us about your device, conformity route, technical file status, and timeline. We will respond within 24 business hours to discuss scope and next steps.